Half-year report · HY
3645.TEDINET S100XFCO
Period2025-06-01 → 2025-11-30
Filed2026-01-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥3.3bn | 2025-06-01 → 2025-11-30 | Cons. | Net sales |
| Revenue | ¥6.1bn | 2024-06-01 → 2025-05-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.9bn | 2024-06-01 → 2024-11-30 | Cons. | Net sales |
| Operating income | ¥94m | 2025-06-01 → 2025-11-30 | Cons. | Operating income |
| Operating income | ¥48m | 2024-06-01 → 2024-11-30 | Cons. | Operating income |
| Ordinary income | ¥165m | 2025-06-01 → 2025-11-30 | Cons. | Ordinary income |
| Ordinary income | ¥135m | 2024-06-01 → 2025-05-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥67m | 2024-06-01 → 2024-11-30 | Cons. | Ordinary income |
| Profit before tax | ¥164m | 2025-06-01 → 2025-11-30 | Cons. | Income before income taxes |
| Profit before tax | ¥59m | 2024-06-01 → 2024-11-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥91m | 2025-06-01 → 2025-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥68m | 2024-06-01 → 2025-05-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥17m | 2024-06-01 → 2024-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥110m | 2025-06-01 → 2025-11-30 | Cons. | Profit loss |
| Net income | ¥1m | 2024-06-01 → 2024-11-30 | Cons. | Profit loss |
| Total assets | ¥4.6bn | at 2025-11-30 | Cons. | Assets |
| Total assets | ¥4.1bn | at 2025-05-31 | Cons. | Assets |
| Total assets | ¥4.4bn | at 2024-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥2.5bn | at 2025-11-30 | Cons. | Liabilities |
| Total liabilities | ¥2.3bn | at 2025-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥2.0bn | at 2025-11-30 | Cons. | Net assets |
| Net assets / equity | ¥1.8bn | at 2025-05-31 | Cons. | Net assets |
| Net assets / equity | ¥1.9bn | at 2024-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.9bn | at 2025-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.5bn | at 2025-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.9bn | at 2025-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.4bn | at 2025-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.4bn | at 2024-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.5bn | at 2024-05-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥248m | 2025-06-01 → 2025-11-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥81m | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥56m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥11m | 2025-06-01 → 2025-11-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥260m | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥23m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥193m | 2025-06-01 → 2025-11-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥219m | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥21m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥9.92 | 2025-06-01 → 2025-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-7.64 | 2024-06-01 → 2025-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-1.89 | 2024-06-01 → 2024-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 42.7% | at 2025-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.0% | at 2025-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.5% | at 2024-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 48
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-06-01 → 2025-11-30 | ¥90,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-06-01 → 2025-11-30 | ¥90,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-06-01 → 2025-11-30 | ¥90,000 |
| Cloud Integrationreportable segment | revenue | 2025-06-01 → 2025-11-30 | ¥221m |
| Cloud Integrationreportable segment | revenue external | 2025-06-01 → 2025-11-30 | ¥221m |
| Cloud Integrationreportable segment | segment profit | 2025-06-01 → 2025-11-30 | ¥48m |
| Mediaplatformreportable segment | revenue | 2025-06-01 → 2025-11-30 | ¥484m |
| Mediaplatformreportable segment | revenue external | 2025-06-01 → 2025-11-30 | ¥484m |
| Mediaplatformreportable segment | segment profit | 2025-06-01 → 2025-11-30 | ¥235m |
| Medical B To Breportable segment | revenue | 2025-06-01 → 2025-11-30 | ¥79m |
| Medical B To Breportable segment | revenue external | 2025-06-01 → 2025-11-30 | ¥76m |
| Medical B To Breportable segment | revenue intersegment | 2025-06-01 → 2025-11-30 | ¥3m |
| Medical B To Breportable segment | segment profit | 2025-06-01 → 2025-11-30 | ¥11m |
| Medical Institution Management Supportreportable segment | revenue | 2025-06-01 → 2025-11-30 | ¥2.5bn |
| Medical Institution Management Supportreportable segment | revenue external | 2025-06-01 → 2025-11-30 | ¥2.5bn |
| Medical Institution Management Supportreportable segment | segment profit | 2025-06-01 → 2025-11-30 | ¥54m |
| —segment total | revenue | 2025-06-01 → 2025-11-30 | ¥3.3bn |
| —segment total | revenue external | 2025-06-01 → 2025-11-30 | ¥3.3bn |
| —segment total | revenue intersegment | 2025-06-01 → 2025-11-30 | ¥3m |
| —segment total | segment profit | 2025-06-01 → 2025-11-30 | ¥347m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-06-01 → 2025-11-30 | ¥3.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-06-01 → 2025-11-30 | ¥3.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-06-01 → 2025-11-30 | ¥3m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-06-01 → 2025-11-30 | ¥347m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-06-01 → 2024-11-30 | ¥908,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-06-01 → 2024-11-30 | ¥908,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-06-01 → 2024-11-30 | ¥908,000 |
| Cloud Integrationreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥219m |
| Cloud Integrationreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥219m |
| Cloud Integrationreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥41m |
| Mediaplatformreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥546m |
| Mediaplatformreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥546m |
| Mediaplatformreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥279m |
| Medical B To Breportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥87m |
| Medical B To Breportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥87m |
| Medical B To Breportable segment | segment profit | 2024-06-01 → 2024-11-30 | −¥11m |
| Medical Institution Management Supportreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥2.0bn |
| Medical Institution Management Supportreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥2.0bn |
| Medical Institution Management Supportreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥83m |
| Pre Symptomatic And Preventive Disease Platformreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥19m |
| Pre Symptomatic And Preventive Disease Platformreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥19m |
| Pre Symptomatic And Preventive Disease Platformreportable segment | segment profit | 2024-06-01 → 2024-11-30 | −¥104m |
| —segment total | revenue | 2024-06-01 → 2024-11-30 | ¥2.9bn |
| —segment total | revenue external | 2024-06-01 → 2024-11-30 | ¥2.9bn |
| —segment total | segment profit | 2024-06-01 → 2024-11-30 | ¥287m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-06-01 → 2024-11-30 | ¥2.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-06-01 → 2024-11-30 | ¥2.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-06-01 → 2024-11-30 | ¥288m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 535
| Item | Context | Value | Unit |
|---|---|---|---|
| Directors compensations sga | Prior1InterimDuration | 91036000 | JPY |
| Directors compensations sga | InterimDuration | 95296000 | JPY |
| Salaries and allowances sga | Prior1InterimDuration | 323800000 | JPY |
| Salaries and allowances sga | InterimDuration | 337167000 | JPY |
| Advertising expenses sga | Prior1InterimDuration | 77239000 | JPY |
| Advertising expenses sga | InterimDuration | 53842000 | JPY |
| Provision of allowance for doubtful accounts sga | Prior1InterimDuration | 2584000 | JPY |
| Provision of allowance for doubtful accounts sga | InterimDuration | -585000 | JPY |
| Provision for bonuses sga | Prior1InterimDuration | 1923000 | JPY |
| Provision for bonuses sga | InterimDuration | 3758000 | JPY |
| Retirement benefit expenses sga | Prior1InterimDuration | 2054000 | JPY |
| Retirement benefit expenses sga | InterimDuration | 2198000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E24982-000MediaplatformReportableSegmentsMember | 545901000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E24982-000MedicalInstitutionManagementSupportReportableSegmentsMember | 2040652000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E24982-000MedicalBToBReportableSegmentsMember | 87451000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E24982-000CloudIntegrationReportableSegmentMember | 218697000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E24982-000PreSymptomaticAndPreventiveDiseasePlatformReportableSegmentMember | 18911000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReportableSegmentsMember | 2911612000 | JPY |
| Revenues from external customers | Prior1InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 908000 | JPY |
| Revenues from external customers | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 2912520000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E24982-000MediaplatformReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E24982-000MedicalInstitutionManagementSupportReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E24982-000MedicalBToBReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E24982-000CloudIntegrationReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E24982-000PreSymptomaticAndPreventiveDiseasePlatformReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E24982-000MediaplatformReportableSegmentsMember | 545901000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E24982-000MedicalInstitutionManagementSupportReportableSegmentsMember | 2040652000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E24982-000MedicalBToBReportableSegmentsMember | 87451000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E24982-000CloudIntegrationReportableSegmentMember | 218697000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E24982-000PreSymptomaticAndPreventiveDiseasePlatformReportableSegmentMember | 18911000 | JPY |
| Net sales | Prior1InterimDuration_ReportableSegmentsMember | 2911612000 | JPY |
| Net sales | Prior1InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 908000 | JPY |
| Net sales | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 2912520000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E24982-000MediaplatformReportableSegmentsMember | 278973000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E24982-000MedicalInstitutionManagementSupportReportableSegmentsMember | 82760000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E24982-000MedicalBToBReportableSegmentsMember | -11446000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E24982-000CloudIntegrationReportableSegmentMember | 41297000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E24982-000PreSymptomaticAndPreventiveDiseasePlatformReportableSegmentMember | -104261000 | JPY |
| Operating income | Prior1InterimDuration_ReportableSegmentsMember | 287324000 | JPY |
| Operating income | Prior1InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 908000 | JPY |
| Operating income | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 288232000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E24982-000MediaplatformReportableSegmentsMember | 484390000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E24982-000MedicalInstitutionManagementSupportReportableSegmentsMember | 2549575000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E24982-000MedicalBToBReportableSegmentsMember | 75582000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E24982-000CloudIntegrationReportableSegmentMember | 220849000 | JPY |
| Revenues from external customers | InterimDuration_ReportableSegmentsMember | 3330398000 | JPY |
| Revenues from external customers | InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 90000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |